Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update - ResearchAndMarkets.com

15 Nov 2022
www.businesswire.com
DUBLIN--(BUSINESS WIRE)--The "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
'Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update'
The publisher's Medical Devices sector report, "Next Generation Sequencing (NGS) Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update' provides comprehensive information about the Next Generation Sequencing (NGS) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based.
Scope
Extensive coverage of the Next Generation Sequencing (NGS) Tests under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Next Generation Sequencing (NGS) Tests and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment/industry
Reasons to Buy
The report enables you to:
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Next Generation Sequencing (NGS) Tests under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product's current stage of development, territory and estimated launch date
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Next Generation Sequencing (NGS) Tests Overview
3 Products under Development
3.1 Next Generation Sequencing (NGS) Tests - Pipeline Products by Stage of Development
3.2 Next Generation Sequencing (NGS) Tests - Pipeline Products by Territory
3.3 Next Generation Sequencing (NGS) Tests - Pipeline Products by Regulatory Path
3.4 Next Generation Sequencing (NGS) Tests - Pipeline Products by Estimated Approval Date
3.5 Next Generation Sequencing (NGS) Tests - Ongoing Clinical Trials
4 Next Generation Sequencing (NGS) Tests - Pipeline Products under Development by Companies
4.1 Next Generation Sequencing (NGS) Tests Companies - Pipeline Products by Stage of Development
4.2 Next Generation Sequencing (NGS) Tests - Pipeline Products by Stage of Development
5 Next Generation Sequencing (NGS) Tests Companies and Product Overview
6 Appendix
6.1 Methodology
6.2 About the Publisher
6.3 Contact the Publisher
6.4 Disclaimer
Companies Mentioned
DCGen Co Ltd
Genetron Health (Beijing) Co Ltd
Laboratory Corp of America Holdings
OncoSpire Genomics
University of Texas Health Science Center at Houston
For more information about this report visit https://www.researchandmarkets.com/r/kwwt24
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.